Fecal Microbiota Transplantation in Combination with Soluble Dietary Fiber for Treatment of Slow Transit Constipation: A Pilot Study

2016 ◽  
Vol 47 (3) ◽  
pp. 236-242 ◽  
Author(s):  
Xiaolong Ge ◽  
Hongliang Tian ◽  
Chao Ding ◽  
Lili Gu ◽  
Yao Wei ◽  
...  
Keyword(s):  
Pilot Study ◽  
Dietary Fiber ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Slow Transit Constipation ◽  
Soluble Dietary Fiber ◽  
Slow Transit ◽  
Transit Constipation

scholarly journals Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0171308 ◽  
Author(s):  
Hongliang Tian ◽  
Xiaolong Ge ◽  
Yongzhan Nie ◽  
Linfeng Yang ◽  
Chao Ding ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Slow Transit Constipation ◽  
Slow Transit ◽  
Transit Constipation

scholarly journals The Fecal Microbiota Transplantation: A Remarkable Clinical Therapy for Slow Transit Constipation in Future

2021 ◽  
Vol 11 ◽  
Author(s):  
Jiafei Liu ◽  
Liqiang Gu ◽  
Mingqing Zhang ◽  
Shiwu Zhang ◽  
Min Wang ◽  
...  
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Treatment Modalities ◽  
Slow Transit Constipation ◽  
Therapeutic Effects ◽  
Intestinal Microbes ◽  
Intestinal Pathogens ◽  
Slow Transit ◽  
Traditional Therapies ◽  
Transit Constipation

Slow transit constipation is a common condition that would be difficult to treat in clinical practice with a widespread incidence in the population. Pharmacotherapy and surgery are common treatment modalities. However, the clinical effect is limited, and patients still suffer from it. As the researchers strived in this field for decades, the profound relationship between slow transit constipation and fecal microbiota transplantation has comprehensively been sustained. It is very pivotal to maintain intestinal homeostasis, the structure function and metabolic function of symbiotic bacteria, which can inhibit the engraftment of intestinal pathogens. This mini review explains the treatment effects and possible mechanisms of the fecal microbiota transplantation in treating slow transit constipation. Simultaneously, it is found that there is significant improvement in the disease by adjusting the intestinal microbes like fecal microbiota transplantation. Fecal microbiota transplantation has efficient therapeutic effects in slow transit constipation compared with traditional therapies.

Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation

2016 ◽  
Vol 50 (10) ◽  
pp. 865-870 ◽  
Author(s):  
Hongliang Tian ◽  
Chao Ding ◽  
Jianfeng Gong ◽  
Xiaolong Ge ◽  
Lynne V. McFarland ◽  
...  
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Slow Transit Constipation ◽  
Slow Transit ◽  
Transit Constipation

scholarly journals Effect of fecal microbiota transplantation in patients with slow transit constipation and the relative mechanisms based on the protein digestion and absorption pathway

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Lulu Xie ◽  
Chen Xu ◽  
Yadong Fan ◽  
Yuwei Li ◽  
Ying Wang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Slow Transit Constipation ◽  
Hamilton Depression Scale ◽  
Protein Digestion ◽  
Slow Transit ◽  
Transit Constipation ◽  
16 S Rrna ◽  
Absorption Pathways

Abstract Background Fecal microbiota transplantation (FMT) is considered an effective treatment for slow transit constipation (STC); nevertheless, the mechanism remains unclear. Methods In this study, eight patients with STC were selected according to the inclusion and exclusion criteria; they then received three treatments of FMT. The feces and serum of STC patients were collected after each treatment and analyzed by integrating 16 s rRNA microbiome and metabolomic analyses. Results The results showed that the percentage of clinical improvement reached 62.5% and the rates of patients’ clinical remission achieved 75% after the third treatment. At the same time, FMT improved the Wexner constipation scale (WCS), the Gastrointestinal Quality-of-Life Index (GIQLI) and Hamilton Depression Scale (HAMD). Fecal microbiome alpha diversity and beta diversity altered significantly after FMT. Analysis of the 16 s rRNA microbiome showed that the numbers of Bacteroidetes (Prevotell/Bacteroides) and Firmicute (Roseburia/Blautia) decreased, whereas Actinobacteria (Bifidobacterium), Proteobacteria (Escherichia), and Firmicute (Lactobacillus) increased after FMT. The metabolomics analyses showed that the stool of FMT-treated patients were characterized by relatively high levels of N-Acetyl-L-glutamate, gamma-L-glutamyl-L-glutamic acid, Glycerophosphocholine, et al., after FMT. Compared with baseline, the serum of treated patients was characterized by relatively high levels of L-Arginine, L-Threonine, Ser-Arg, Indoleacrylic acid, Phe-Tyr, 5-L-Glutamyl-L-alanine, and lower levels of Erucamide after the treatment. The correlation analysis between the metabolites and gut microbiota showed a significant correlation. For example, L-Arginine was positively correlated with lactobacillus, et al. L-Threonine was positively correlated with Anaerovibrio, Sediminibacterium but negatively correlated with Phascolarctobacterium. Erucamide had significant negative correlations with Sediminibacterium and Sharpea, while being positively correlated with Phascolarctobacterium. Enriched KEGG pathways analysis demonstrated that the protein digestion and absorption pathways gradually upregulated with the increase of FMT frequency. The L-Arginine and L-Threonine were also involved in the pathway. A large amount of Na + was absorbed in the pathway, so that it might increase mucus secretion and electrical excitability of GI smooth muscle. Conclusions Therefore, we speculated that FMT changed the patients’ gut microbiota and metabolites involved in the protein digestion and absorption pathways, thereby improving the symptoms of STC. Study on the effectiveness and safety of FMT in the treatment of STC. The study was reviewed and approved by Ethics Committee of Tianjin People's Hospital (ChiCTR2000033227) in 2020.

scholarly journals Effect of Fecal Microbiota Transplantation in Patients With Slow Transit Constipation and the Relative Mechanisms Based On the Protein Digestion and Absorption Pathway

2021 ◽  
Author(s):  
Lulu Xie ◽  
Chen Xu ◽  
Yadong Fan ◽  
Yuwei Li ◽  
Ying Wang ◽  
...  
Keyword(s):  
16S Rrna ◽  
Gut Microbiota ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Slow Transit Constipation ◽  
Hamilton Depression Scale ◽  
Protein Digestion ◽  
Slow Transit ◽  
Transit Constipation ◽  
Absorption Pathways

Abstract Background: Fecal microbiota transplantation (FMT) is considered an effective treatment for slow transit constipation (STC); nevertheless, the mechanism remains unclear. Methods: In this study, eight patients with STC were selected according to the inclusion and exclusion criteria; they then received three treatments of FMT. The feces and serum of STC patients were collected after each treatment and analyzed by integrating 16s rRNA microbiome and metabolomic analyses. Results: The results showed that the percentage of clinical improvement reached 62.5% and the rates of patients’ clinical remission achieved 75% after the third treatment. At the same time, FMT improved the Wexner constipation scale (WCS), the Gastrointestinal Quality-of-Life Index (GIQLI) and Hamilton Depression Scale (HAMD). Fecal microbiome alpha diversity and beta diversity altered significantly after FMT. Analysis of the 16s rRNA microbiome showed that the numbers of Bacteroidetes (Prevotell/Bacteroides) and Firmicute (Roseburia/Blautia) decreased, whereas Actinobacteria (Bifidobacterium), Proteobacteria (Escherichia), and Firmicute (Lactobacillus) increased after FMT. The metabolomics analyses showed that the stool of FMT-treated patients were characterized by relatively high levels of N-Acetyl-L-glutamate, gamma-L-Glutamyl-L-glutamic acid, Glycerophosphocholine, et al, after FMT. Meanwhile, the serum of treated patients was characterized by relatively high levels of L-Arginine, L-Threonine, Ser-Arg, Indoleacrylic acid, Phe-Tyr, 5-L-Glutamyl-L-alanine, and lower levels of Erucamide after the treatment. The correlation analysis between the metabolites and gut microbiota showed a significant correlation. For example, L‐Arginine was positively correlated with lactobacillus, et al. L-Threonine was positively correlated with Anaerovibrio, Sediminibacterium but negatively correlated with Phascolarctobacterium. Erucamide had significant negative correlations with Sediminibacterium and Sharpea, while being positively correlated with Phascolarctobacterium. Enriched KEGG pathways analysis demonstrated that the protein digestion and absorption pathways gradually upregulated with the increase of FMT frequency. The L‐Arginine and L-Threonine were also involved in the pathway. A large amount of Na+ was absorbed in the pathway, so that it might increase mucus secretion and electrical excitability of GI smooth muscle. Conclusions: Therefore, we speculated that FMT changed the patients’ gut microbiota and metabolites involved in the protein digestion and absorption pathways, thereby improving the symptoms of STC.Study on the effectiveness and safety of FMT in the treatment of STC. The study was reviewed and approved by Ethics Committee of Tianjin People's Hospital (ChiCTR2000033227) in 2020.

Sign in / Sign up

Export Citation Format

Share Document